home / stock / nvs / nvs articles

NVS Articles, Novartis AG - From 01/11/24

Stock Information
Company Name: Novartis AG
Stock Symbol: NVS
Market: NYSE
Website: novartis.com
Menu
NVS NVS Quote NVS Short NVS News NVS Articles NVS Message Board
Get NVS Alerts

News, Short Squeeze, Breakout and More Instantly...
Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition | Benzinga

Novartis AG (NYSE: NVS) has decided to step back from pursuing the Cytokinetics Inc (NASDAQ: CYTK) acquisition, dealing a blow ...
What's Been Happening With Cytokinetics Stock? | Benzinga

Cytokinetics, Incorporated (NASDAQ: CYTK) shares are trading lower on Tuesday, pulling back from Monday strength. What To Know: Cytokinetics stock ...

Why Is Heart Failure Drug-Focused Cytokinetic Stock Trading Higher Today? | Benzinga

Cytokinetics Inc (NASDAQ: CYTK) shares are trading higher after a report on potential takeover talks with Novartis AG (NYSE: NVS). T...

Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today? | Benzinga

Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an update on its business. The co...
Voyager Therapeutics Stock Tanked After-Hours - Here's Why | Benzinga

Voyager Therapeutics, Inc. (NASDAQ: VYGR) shares are trading lower in Thursday's after-hours session after announcing a proposed public of...

Why Is Gene Therapy Focused Voyager Therapeutics Stock Soaring Today? | Benzinga

Voyager Therapeutics Inc (NASDAQ: VYGR) announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsi...

Why Is Neurology Focused Cingulate Stock Trading Higher Today? | Benzinga

On Tuesday, Cingulate Inc (NASDAQ: CING) received FDA guidance for CTx-1301 (dexmethylphenidate), its lead investigational prod...
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug | Benzinga

The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidn...

Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside | Benzinga

RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a bu...

Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug | Benzinga

Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivot...
Previous 10 Next 10